

### REMARKS

In the Restriction Requirement mailed October 25, 2007, in the above-identified application, the Examiner identified ten (10) separate groups, Groups I-X.

Applicants hereby provisionally elect, with traverse, to prosecute the claims of Group I, which includes Claims 1-14 and 53-60. Claims 15-49 and 66-77 are being withdrawn as being drawn to non-elected subject matter. Applicants have amended the claims in response to the restriction requirement and to put the claims into condition for substantive examination. More specifically, Claims 1-3, 5-10, 12-14 and 53-60 have been amended. Support for the amendments is found throughout the specification as filed (e.g., pages 5, 12-15, and 20-27, and the claims as originally filed). Claims 50-52 and 61-65 have been canceled and new Claims 78-88 have been added. Support for new Claims 79-88 can be found throughout the specification as filed, including pages 5, 12 and 14, and the claims as filed.

With respect to the merits of the restriction requirement between Groups I and V, Applicants traverse the restriction requirement on the ground that examination of Ar<sub>1</sub> and Ar<sub>2</sub> being unsubstituted or substituted aryl, or unsubstituted or substituted heteroaryl groups does not place an undue burden on the PTO. As stated in M.P.E.P. § 803, "[i]f the search and examination of all the claims in an application can be made without serious burden, the examiner must examine them on the merits, even though they include claims to independent and distinct invention." The search of the compounds of Group I in which Ar<sub>1</sub> and Ar<sub>2</sub> are unsubstituted or substituted aryl, or unsubstituted or substituted heteroaryl groups do not require a separate search; therefore, it does not impose an undue burden on the Examiner. Moreover, this application claims priority to two issued U.S. Patents, U.S. Patent Nos. 6,815,458 and 6,756,393, in which Ar<sub>1</sub> and Ar<sub>2</sub> were searched as being both unsubstituted or substituted aryl, or unsubstituted or substituted heteroaryl groups. Accordingly, Applicants respectfully request the Examiner to reconsider the restriction between Groups I and V, and modify the restriction such that Ar<sub>1</sub> and Ar<sub>2</sub> can be unsubstituted or substituted aryl, or unsubstituted or substituted heteroaryl groups.

Applicants reserve the right to seek rejoinder of claims pertaining to the non-elected subject matter pursuant to M.P.E.P. § 800. For example, upon allowance of the elected claims,

Applicants reserve the right to seek rejoinder pursuant to M.P.E.P. § 821.04. Additionally, Applicants reserve the right to file continuation, divisional, or continuation-in-part applications to pursue the withdrawn subject matter.

The Examiner has also requested election of a single disclosed species. In response to the Examiner's request, Applicants elect the compound 2-(4-*i*-Propoxyphenyl)-*N*-(4-methylbenzyl)-*N*-(1-methylpiperidin-4-yl) acetamide, described, e.g., on page 116 of the specification. Applicants respectfully submit that Claims 1-5, 8-12, 14, 55, 60 and 82-88 of the pending claims read on the elected species.

Applicants also respectfully request the amendment of lines 6-7 on page 74 of the present specification as shown herein. This amendment is supported by the specification as filed. If one skilled in the art followed the synthetic procedure of Example 50 with the starting materials 50ELH87 (2-(4-methoxyphenyl)-*N*-(4-methylbenzyl)-*N*-(piperidin-4-yl) acetamide) and isopropylbromide, the product would be 2-(4-methoxyphenyl)-*N*-(4-methylbenzyl)-*N*-(isopropylpiperidin-4-yl) acetamide. Accordingly, this amendment does not present an issue of new matter.

#### **No Disclaimers or Disavowals**

Although the present communication may include alterations to the application or claims, or characterizations of claim scope or referenced art, the Applicants are not conceding in this application that previously pending claims are not patentable over the cited references. Rather, any alterations or characterizations are being made to facilitate expeditious prosecution of this application. The Applicants reserve the right to pursue at a later date any previously pending or other broader or narrower claims that capture any subject matter supported by the present disclosure, including subject matter found to be specifically disclaimed herein or by any prior prosecution. Accordingly, reviewers of this or any parent, child or related prosecution history shall not reasonably infer that the Applicants have made any disclaimers or disavowals of any subject matter supported by the present application.

**Application No.:** 10/802,970  
**Filing Date:** MARCH 16, 2004

**Co-Pending Applications of Assignee**

Applicant wishes to draw the Examiner's attention to the following co-pending applications of the present application's assignee.

Serial Number	Title	Filed
11/417790	AZACYCLIC COMPOUNDS	May 3, 2006
11/417782	AZACYCLIC COMPOUNDS	May 3, 2006
11/299566	N-SUBSTITUTED PIPERIDINE DERIVATIVES AS SEROTONIN RECEPTOR AGENTS	Dec. 12, 2005
11/417866	N-SUBSTITUTED PIPERIDINE DERIVATIVES AS SEROTONIN RECEPTOR AGENTS	May 3, 2006
11/418353	N-SUBSTITUTED PIPERIDINE DERIVATIVES AS SEROTONIN RECEPTOR AGENTS	May 3, 2006
10/759561	SELECTIVE SEROTONIN 2A/2C RECEPTOR INVERSE AGONISTS AS THERAPEUTICS FOR NEURODEGENERATIVE DISEASES	Jan. 15, 2004
11/416527	SELECTIVE SEROTONIN 2A/2C RECEPTOR INVERSE AGONISTS AS THERAPEUTICS FOR NEURODEGENERATIVE DISEASES	May 3, 2006
11/416855	SELECTIVE SEROTONIN 2A/2C RECEPTOR INVERSE AGONISTS AS THERAPEUTICS FOR NEURODEGENERATIVE DISEASES	May 3, 2006
11/416594	SELECTIVE SEROTONIN 2A/2C RECEPTOR INVERSE AGONISTS AS THERAPEUTICS FOR NEURODEGENERATIVE DISEASES	May 3, 2006
11/235558	SYNTHESIS OF N-(4-FLUOROBENZYL)-N-(1-METHYLPYPERIDIN-4-YL)-N'-(4-(2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND CRYSTALLINE FORMS	Sept. 26, 2005
11/235381	SALTS OF N-(4-FLUOROBENZYL)-N-(1-METHYLPYPERIDIN-4-YL)-N'-(4-(2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND THEIR PREPARATION	Sept. 26, 2005
11/418341	SYNTHESIS OF N-(4-FLUOROBENZYL)-N-(1-METHYLPYPERIDIN-4-YL)-N'-(4-(2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND CRYSTALLINE FORMS	May 3, 2006

Application No.: 10/802,970  
Filing Date: MARCH 16, 2004

11/417447	SYNTHESIS OF N-(4-FLUOROBENZYL)-N-(1-METHYLPIPERIDIN-4-YL)-N'-(4-(2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND CRYSTALLINE FORMS	May 3, 2006
11/749115	SYNTHESIS OF N-(4-FLUOROBENZYL)-N-(1-METHYLPIPERIDIN-4-YL)-N'-(4-(2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND CRYSTALLINE FORMS	May 15, 2007

Applicants respectfully submit that Claims 1-14, 53-60 and 79-88 are in condition for examination. If there are any questions, the Examiner is invited to contact the undersigned at the telephone number listed below. Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: Dec. 21, 2007

By: 

Daniel Hart  
Registration No. 40,637  
Attorney of Record  
Customer No. 20995  
(619) 235-8550

AMEND

4551014.2  
111907